Pharmaceutical and bio-pharma companies use Mastermind Curated Genomic Datasets to inform precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx biomarkers in regulatory submissions with empirical evidence.
Visit us at the Genomenon booth at CB & CDx Boston on September 11th & 12th for a demo, or request a meeting below.
Characterizing Targeted Cancer Therapies via a Structural Alteration Database
Mark Kiel, MD, PhD
Founder and CSO, Genomenon
Thursday, September 12, 2019 – 2:30 p.m.
LET’S MEET IN BOSTON
Request a meeting to discuss how Mastermind’s curated datasets can provide a comprehensive genomic landscape for any disease.